GlassScriptPhysician profile
Wasim Ahmar
NPI 1528061330
$10,705.94
in general payments reported to CMS, 2019-2025
46 companies · $974 in 2025
The $974 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,058 · 2020: $1,170 · 2021: $1,668 · 2022: $1,528 · 2023: $1,907 · 2024: $2,402 · 2025: $974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,576 · Travel and Lodging: $696 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,575.57 |
| Travel and Lodging | $696.26 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,601.46 | 2023-2025 | Venaseal, Micra, Harmony |
| Cardiovascular Systems INC. | $841.84 | 2020 | |
| Biotronik INC. | $672.52 | 2021-2025 | Biomonitor |
| Janssen Pharmaceuticals, INC | $590.55 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $553.59 | 2019-2025 | Camzyos, Eliquis |
| Kestra Medical Technology Services, INC. | $542.13 | 2024-2025 | Assure Wcd |
| Abbott Laboratories | $520.27 | 2019-2024 | Ensite Precision, Aveir, Confirm Rx |
| Novo Nordisk INC | $394.78 | 2021-2025 | Ozempic |
| Amgen INC. | $372.13 | 2019-2025 | Krystexxa, Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $364.80 | 2019-2025 | |
| Bard Peripheral Vascular, INC. | $345.37 | 2021 | |
| Philips North America LLC | $335.80 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $311.63 | 2021-2023 | Verquvo, Belsomra |
| Astellas Pharma US INC | $287.03 | 2019-2022 | |
| Medicomp INC | $233.16 | 2023 | Telepatch Cardiac Monitor |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celonova Biosciences, INC. | $180.87 | 2019 | |
| Abiomed | $180.77 | 2022-2023 | Impella |
| Medtronic Vascular, INC. | $178.13 | 2019-2020 | |
| Impulse Dynamics (USA) INC. | $177.75 | 2022-2024 | Optimizer, Optimizer |
| Stryker Corporation | $171.83 | 2021 | |
| Pfizer INC. | $169.52 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $159.47 | 2019-2023 | Farxiga |
| Boston Scientific Corporation | $156.88 | 2019-2025 | Varithena Administration Pack |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $154.38 | 2022-2024 | Lifevest |
| Terumo Medical Corporation | $142.95 | 2019 | |
| Biosense Webster, INC. | $121.44 | 2023 | Carto 3 |
| Avantec Vascular Corporation | $116.67 | 2023 | |
| Esperion Therapeutics, INC. | $111.76 | 2020-2023 | Nexletol |
| Teleflex LLC | $105.63 | 2025 | Turnpike |
| Cardiva Medical, INC. | $98.04 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.56 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $51.75 | 2021-2024 | Onpattro |
| Baxter Healthcare | $49.96 | 2023-2024 | Hillrom - Cardiac Ambulatory Monitor |
| Chiesi USA, INC. | $47.03 | 2020-2023 | Kengreal |
| Edwards Lifesciences Corporation | $45.85 | 2019-2020 | |
| Cvrx, INC. | $31.93 | 2025 | Barostim Neo System |
| Kiniksa Pharmaceuticals International, Plc | $28.72 | 2024 | Arcalyst |
| Livanova USA, INC. | $25.83 | 2022 | |
| Siemens Medical Solutions USA, INC. | $24.27 | 2022 | |
| Sanofi-Aventis U.S. LLC | $22.98 | 2019 | |
| Ge Healthcare | $21.99 | 2025 | |
| Daiichi Sankyo INC. | $20.05 | 2023 | Injectafer |
| Atricure, INC. | $18.54 | 2021 | |
| Angiodynamics, INC. | $15.43 | 2019 | |
| Bardy Diagnostics, INC. | $15.00 | 2021 | |
| Amarin Pharma, INC. | $13.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wasim Ahmar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.